Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With Psoriasis

"1. Cohort 1 : Single-dose administration, intravenous injection~ * Dose 1(Starting dose) : 1.0\*10\^6 cells/kg~ * Dose 2 : 2.0\*10\^6 cells/kg~ * Dose 3 : 3.0\*10\^6 cells/kg~2. Cohort 2 : Multiple-dose administration, intravenous injections (Week 0, Week 4)~ * Dose 1(Starting dose) : 1.0\*10\^6 cells/kg~ * Dose 2 : 2.0\*10\^6 cells/kg~ * Dose 3 : 3.0\*10\^6 cells/kg"